Efficient human hematopoietic cell transduction using RD114- and GALV-pseudotyped retroviral vectors produced in suspension and serum-free media

Human Gene Therapy

Volumn 20, Issue 9, 2009, Pages 966-974

  Ghani, Karim ^a   Wang, Xiuyan ^b   De Campos Lima, Pedro Otavio ^a   Olszewska, Malgorzata ^b   Kamen, Amine ^c   Rivière, Isabelle ^b   Caruso, Manuel ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RETROVIRUS VECTOR;

ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; FREEZE THAWING; GENETIC TRANSDUCTION; GIBBON LEUKEMIA VIRUS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MOLONEY LEUKEMIA ONCOVIRUS; NONHUMAN; PSEUDOTYPING; SERUM; SUSPENSION CELL CULTURE; VIRUS PARTICLE;

ANIMALS; ANTIGENS, CD34; CELL LINE; CULTURE MEDIA; CULTURE MEDIA, SERUM-FREE; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA VIRUS, GIBBON APE; RETROVIRIDAE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; VIRAL ENVELOPE PROTEINS; VIRUS ASSEMBLY;

GIBBON APE LEUKEMIA VIRUS; MOLONEY MURINE LEUKEMIA VIRUS;

EID: 70349148287     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.001     Document Type: Article

References (35)

1. Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., Marinello, E., Cattaneo, F., Vai, S., Servida, P., Miniero, R., Roncarolo, M.G., and Bordignon, C. (2002). Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410-2413.
2. Aiuti, A., Cattaneo, F., Galimberti, S., Benninghoff, U., Cassani, B., Callegaro, L., Scaramuzza, S., Andolfi, G., Mirolo, M., Brigida, I., Tabucchi, A., Carlucci, F., Eibl, M., Aker, M., Sla-vin, S., Al-Mousa, H., Al Ghonaium, A., Ferster, A., Dup-penthaler, A., Notarangelo, L., Wintergerst, U., Buckley, R.H., Bregni, M., Marktel, S., Valsecchi, M.G., Rossi, P., Ciceri, F., Miniero, R., Bordignon, C., and Roncarolo, M.G. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360, 447-458.
3. Appelbaum, F.R. (2001). Haematopoietic cell transplantation as immunotherapy. Nature 411, 385-389.
4. Arai, T., Takada, M., Ui, M., and Iba, H. (1999). Dose-dependent transduction of vesicular stomatitis virus G protein-pseudotyped retrovirus vector into human solid tumor cell lines and murine fibroblasts. Virology 260, 109-115.
5. Bonini, C., Bondanza, A., Perna, S.K., Kaneko, S., Traversari, C., Ciceri, F., and Bordignon, C. (2007). The suicide gene therapy challenge: How to improve a successful gene therapy approach. Mol. Ther. 15, 1248-1252.
6. Brenner, S., Whiting-Theobald, N.L., Linton, G.F., Holmes, K.L., Anderson-Cohen, M., Kelly, P.F., Vanin, E.F., Pilon, A.M., Bodine, D.M., Horwitz, M.E., and Malech, H.L. (2003). Concentrated RD114-pseudotyped MFGS-gp91phox vector achieves high levels of functional correction of the chronic granulomatous disease oxidase defect in NOD=SCID=b2-microglobulin-=- repopulating mobilized human peripheral blood CD34+ cells. Blood 102, 2789-2797.
7. Brentjens, R.J., Hollyman, D.R., Weiss, M., Stefanski, J., Przy-bylowski, M., Bartido, S., Borquez-Ojeda, O., Taylor, C., Hosey, J., Heaney, M., Sadelain, M., and Riviere, I. (2008). A phase I trial for the treatment of chemo-refractory chronic lymphocytic leukemia with CD19-targeted autologous T cells. Mol. Ther. 16, S142.
8. Broussau, S., Jabbour, N., Lachapelle, G., Durocher, Y., Tom, R., Transfiguracion, J., Gilbert, R., and Massie, B. (2008). Inducible packaging cells for large-scale production of len-tiviral vectors in serum-free suspension culture. Mol. Ther. 16, 500-507.
9. Budak-Alpdogan, T., Przybylowski, M., Gonen, M., Sadelain, M., Bertino, J., and Riviere, I. (2006). Functional assessment of the engraftment potential of gammaretrovirus-modified CD34+ cells, using a short serum-free transduction protocol. Hum. Gene Ther. 17, 780-794.
10. Cavazzana-Calvo, M., Hacein-Bey, S., De Saint Basile, G., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.L., Bousso, P., Deist, F.L., and Fischer, A. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-672. (Pubitemid 30241569)
11. Ciceri, F., Bonini, C., Gallo-Stampino, C., and Bordignon, C. (2005). Modulation of GvHD by suicide-gene transduced donor T lymphocytes: Clinical applications in mismatched transplantation. Cytotherapy 7, 144-149.
12. Ciceri, F., Bonini, C., Marktel, S., Zappone, E., Servida, P., Ber-nardi, M., Pescarollo, A., Bondanza, A., Peccatori, J., Rossini, S., Magnani, Z., Salomoni, M., Benati, C., Ponzoni, M., Call-egaro, L., Corradini, P., Bregni, M., Traversari, C., and Bor-dignon, C. (2007). Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 109, 4698-4707.
13. Fischer, A., and Cavazzana-Calvo, M. (2008). Gene therapy of inherited diseases. Lancet 371, 2044-2047.
14. Gallardo, H.F., Tan, C., Ory, D., and Sadelain, M. (1997). Recombinant retroviruses pseudotyped with the vesicular sto-matitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood 90, 952-957.
15. Gaspar, H.B., Parsley, K.L., Howe, S., King, D., Gilmour, K.C., Sinclair, J., Brouns, G., Schmidt, M., Von Kalle, C., Barington, T., Jakobsen, M.A., Christensen, H.O., Al Ghonaium, A., White, H.N., Smith, J.L., Levinsky, R.J., Ali, R.R., Kinnon, C., and Thrasher, A.J. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gam-maretroviral vector. Lancet 364, 2181-2187.
16. Ghani, K., Garnier, A., Coelho, H., Transfiguracion, J., Trudel, P., and Kamen, A. (2006). Retroviral vector production using suspension-adapted 293GPG cells in a 3L acoustic filter-based perfusion bioreactor. Biotechnol. Bioeng. 95, 653-660.
17. Ghani, K., Cottin, S., Kamen, A., and Caruso, M. (2007). Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media. Gene Ther. 14, 1705-1711.
18. Jensen, M.C., Popplewell, L., Digiusto, D.L., Kalos, M., Cooper, L.J., Raubitschek, A., and Forman, S.J. (2007). A first-in-human clinical trial of adoptive therapy using CD19-specific chimeric antigen receptor re-directed T cells for recurrent=refractory follicular lymphoma. Mol. Ther. 15, S142.
19. Kiem, H.P., Heyward, S., Winkler, A., Potter, J., Allen, J.M., Miller, A.D., and Andrews, R.G. (1997). Gene transfer into marrow repopulating cells: Comparison between amphotropic and gibbon ape leukemia virus pseudotyped retroviral vectors in a competitive repopulation assay in baboons. Blood 90, 4638-4645.
20. Lucas, M.L., Seidel, N.E., Porada, C.D., Quigley, J.G., Anderson, S.M., Malech, H.L., Abkowitz, J.L., Zanjani, E.D., and Bodine, D.M. (2005). Improved transduction of human sheep re- populating cells by retrovirus vectors pseudotyped with feline leukemia virus type C or RD114 envelopes. Blood 106, 51-58.
21. Merten, O.W. (2004). State-of-the-art of the production of retro-viral vectors. J. Gene Med. 6(Suppl. 1), S105-S124.
22. Miller, A.D., Garcia, J.V., Von Suhr, N., Lynch, C.M., Wilson, C., and Eiden, M.V. (1991). Construction and properties of ret-rovirus packaging cells based on gibbon ape leukemia virus. J. Virol. 65, 2220-2224.
23. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P., Zheng, Z., Nahvi, A., De Vries, C.R., Rogers-Freezer, L.J., Mavroukakis, S.A., and Rosenberg, S.A. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129.
24. Murphy, A., Westwood, J.A., Teng, M.W., Moeller, M., Darcy, P.K., and Kershaw, M.H. (2005). Gene modification strategies to induce tumor immunity. Immunity 22, 403-414.
25. Onodera, M., Nelson, D.M., Yachie, A., Jagadeesh, G.J., Bunnell, B.A., Morgan, R.A., and Blaese, R.M. (1998). Development of improved adenosine deaminase retroviral vectors. J. Virol. 72, 1769-1774.
26. Orlic, D., Girard, L.J., Jordan, C.T., Anderson, S.M., Cline, A.P., and Bodine, D.M. (1996). The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hema-topoietic stem cells is low and correlates with the efficiency of retrovirus transduction. Proc. Natl. Acad. Sci. U.S.A. 93, 11097-11102.
27. Ott, M.G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kuhlcke, K., Schilz, A., Kunkel, H., Naundorf, S., Brinkmann, A., Deichmann, A., Fischer, M., Ball, C., Pilz, I., Dunbar, C., Du, Y., Jenkins, N.A., Copeland, N.G., Luthi, U., Hassan, M., Thrasher, A.J., Hoelzer, D., Von Kalle, C., Seger, R., and Grez, M. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. at. Med. 12, 401-409.
28. Qiao, J., Roy, V., Girard, M.-H., and Caruso, M. (2002). High translation efficiency is mediated by the encephalomyocarditis virus IRES if the natural sequence surrounding the 11th AUG is retained. Hum. Gene Ther. 13, 881-887.
29. Relander, T., Johansson, M., Olsson, K., Ikeda, Y., Takeuchi, Y., Collins, M., and Richter, J. (2005). Gene transfer to re- populating human CD34+ cells using amphotropic-, GALV-, or RD114-pseudotyped HIV-1-based vectors from stable producer cells. Mol. Ther. 11, 452-459.
30. Sadelain, M., Riviere, I., and Brentjens, R. (2003). Targeting tu-mours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3, 35-45.
31. Sandrin, V., Boson, B., Salmon, P., Gay, W., Negre, D., Le Grand, R., Trono, D., and Cosset, F.L. (2002). Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 100, 823-832.
32. Segura, M.M., Kamen, A., and Garnier, A. (2006). Downstream processing of oncoretroviral and lentiviral gene therapy vectors. Biotechnol. Adv. 24, 321-337.
33. Seppen, J., Barry, S., Lam, G.M., Ramesh, N., and Osborne, W.R. (2000). Retroviral preparations derived from PA317 packaging cells contain inhibitors that copurify with viral particles and are devoid of viral vector RNA. Hum. Gene Ther. 11, 771-775.
34. Slingsby, J.H., Baban, D., Sutton, J., Esapa, M., Price, T., Kings-man, S.M., Kingsman, A.J., and Slade, A. (2000). Analysis of 4070A envelope levels in retroviral preparations and effect on target cell transduction efficiency. Hum. Gene Ther. 11, 1439-1451.
35. Strang, B.L., Ikeda, Y., Cosset, F.L., Collins, M.K., and Takeuchi, Y. (2004). Characterization of HIV-1 vectors with gammare-trovirus envelope glycoproteins produced from stable packaging cells. Gene Ther. 11, 591-598.